B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2024

DelveInsight's, "B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2024" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

B-Cell Non-Hodgkin Lymphoma: Understanding

B-Cell Non-Hodgkin Lymphoma: Overview

B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that originates from abnormal B lymphocytes, a type of white blood cell that is part of the immune system. It is the most common form of NHL, accounting for over 85% of cases. B-cell NHL can be further classified into various subtypes based on the specific characteristics of the cancer cells, such as their appearance under a microscope, the presence of certain proteins on their surface, and their genetic features. The most prevalent subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. B-cell NHL can develop in lymph nodes or other lymphoid tissues, and it may also affect extralymphatic organs such as the gastrointestinal tract. B-cell non-Hodgkin lymphoma presents with various symptoms that can include painless swelling of lymph nodes, unexplained fever, drenching night sweats, persistent fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. These symptoms, when occurring together, are referred to as B symptoms and are significant for prognosis and staging of the disease.

Diagnosing B-cell non-Hodgkin lymphomas, particularly those composed of small- to intermediate-sized cells, poses significant challenges due to morphological similarities with reactive lymphadenopathies and among different lymphoma subtypes. Ancillary techniques such as immunohistochemistry and flow cytometry are essential for accurate diagnosis but must be interpreted in conjunction with morphological and clinical information to avoid errors. Recognizing specific cytologic features is critical for guiding the selection of these tests, which help confirm or refute a provisional diagnosis. The most commonly confused B-cell non-Hodgkin lymphomas based on cytology alone include marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and lymphoplasmacytic lymphoma. Due to these complexities, a lymph node biopsy is often necessary to definitively diagnose and classify the lymphoma.

Treatment for B-cell non-Hodgkin lymphoma (NHL) varies based on the disease stage and subtype, aiming to cure localized cases and manage advanced stages with more complex therapies. For localized B-cell NHL, radiation therapy with tailored doses is often employed. Advanced B-cell NHL may be treated with monoclonal antibody therapy, such as Rituximab, combination chemotherapy regimens like R-CHOP, and participation in clinical trials for new treatments. Patients with resolved hepatitis B virus (HBV) infections need monitoring and may require prophylactic nucleoside therapy to prevent reactivation. Treatment strategies are personalized, focusing on eradicating cancerous cells while effectively managing side effects to improve patient outcomes.

"B-Cell Non-Hodgkin Lymphoma- Pipeline Insight, 2024" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the B-Cell Non-Hodgkin Lymphoma pipeline landscape is provided which includes the disease overview and B-Cell Non-Hodgkin Lymphoma treatment guidelines. The assessment part of the report embraces, in depth B-Cell Non-Hodgkin Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, B-Cell Non-Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence B-Cell Non-Hodgkin Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve B-Cell Non-Hodgkin Lymphoma.

B-Cell Non-Hodgkin Lymphoma Emerging Drugs Chapters

This segment of the B-Cell Non-Hodgkin Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

B-Cell Non-Hodgkin Lymphoma Emerging Drugs

Valemetostat: Daiichi Sankyo

Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.

MB-106: Mustang Bio

MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.

CB-010: Caribou Biosciences

CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.

LP-284: Lantern Pharma

LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern's RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.

Further product details are provided in the report........

B-Cell Non-Hodgkin Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different B-Cell Non-Hodgkin Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in B-Cell Non-Hodgkin Lymphoma
• There are approx. 75+ key companies which are developing the therapies for B-Cell Non-Hodgkin Lymphoma. The companies which have their B-Cell Non-Hodgkin Lymphoma drug candidates in the most advanced stage, i.e. Phase II include, Daiichi Sankyo.
• Phases

DelveInsight's report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

B-Cell Non-Hodgkin Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses B-Cell Non-Hodgkin Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging B-Cell Non-Hodgkin Lymphoma drugs.

B-Cell Non-Hodgkin Lymphoma Report Insights

• B-Cell Non-Hodgkin Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

B-Cell Non-Hodgkin Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing B-Cell Non-Hodgkin Lymphoma drugs?
• How many B-Cell Non-Hodgkin Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of B-Cell Non-Hodgkin Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the B-Cell Non-Hodgkin Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for B-Cell Non-Hodgkin Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Xencor
• MEI Pharma
• Celldex Therapeutics
• TG Therapeutics
• Shanghai Unicar-Therapy Bio-medicine Technology
• Chia Tai Tianqing Pharmaceutical Group
• Mustang Bio
• Novartis
• Loxo Oncology
• Genmab
• Nkarta
• Nurix Therapeutics
• Prelude Therapeutics

Key Products

• XmAb13676
• Voruciclib
• Varlilumab
• TG-1801
• U16
• TQB3820
• MB-106
• YTB323
• Pirtobrutinib
• Epcoritamab
• NKX019
• NX-5948
• PRT543